Orlistat, a well-known OTC weight loss drug, is an emerging pharmaceutical enterprise with strong pharmaceutical R&D and innovation capabilities, integrating R&D/production/sales
Founded in 2001, Chongqing Zhien Pharmaceutical Co., Ltd. is an emerging pharmaceutical enterprise based in Chongqing integrating R&D, production and sales, and is a group company integrating three major R&D centers, API production base, preparation production base and sales headquarters of Liangjiang Engineering Center, Chiral Engineering Center and New Drug Design Engineering Center.
Plant En Pharmaceuticals has extensive experience in R&D. At present, 33 new drug certificates, 32 clinical approvals and 51 production approvals have been obtained. He has applied for dozens of national invention patents, including 2 foreign patents and 12 domestic patents. The company has carried out 32 R&D projects, undertaken more than 70 various topics including major national new drug creation projects ("11.5" and "12.5"), and won dozens of national and provincial awards. At present, the research projects involve nervous system drugs, metabolic system drugs, digestive system drugs and other drugs, among which nervous system drugs have become the main direction of the company's development, including 2 new drugs in class 1 of chemical drugs and 1 new drug in class 5 of traditional Chinese medicine.
Zhien Pharmaceutical has strong industrialization capabilities, and its production capacity is gradually expanding. The existing API production base has an annual production capacity of more than 40 tons, and the new 82,000 square API production base will increase the production capacity to 60 tons ~ 80 tons per year, and the quality and production capacity of the core API variety orlistat have reached the international advanced level, and the products have been sold well in Brazil, Australia, Germany, Poland, Singapore and South Korea, and have submitted marketing applications in the United States and India, and the international market will be further expanded in the future. The existing preparation production line can produce capsules, granules, tablets, suppositories and other dosage forms, and the preparation production line under construction will add lyophilized dosage forms, small/large volume injections and other dosage forms, and the construction area of the preparation industrialization base under construction is 33,330 square meters.
The company has abundant products and sufficient follow-up products. At present, the main products are orlistat, donepezil hydrochloride, ropinirole hydrochloride, mesulfonilast, etc., and the key products to be launched soon include talixaxol hydrochloride and landilolol hydrochloride.
Plant En Pharmaceuticals has a strong network of distributors from the primary market to the end market. At present, it has more than 500 retail terminal and hospital terminal sales personnel. The products cover more than 2,000 hospitals and 40,000 pharmacies in 30 cities. In terms of foreign trade, APIs are exported to more than 20 countries around the world.
The company adheres to the motto of "Wood is straight from the heart, plant medicine is benevolent", and the development goal is "to create a leading enterprise in China's medicine and health services". With the support of a strong pharmaceutical R&D team, efficient medical registration capabilities, extensive and solid pharmaceutical channel network, professional marketing and sales capabilities, authoritative government affairs and cooperation capabilities of professional institutions, the company has become a well-known high-tech pharmaceutical enterprise in the industry.
